Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin

Oncogene

Volumn 29, Issue 29, 2010, Pages 4225-4236

  Wang, S ^a   Huang, X ^a   Lee, C K ^a   Liu, B ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer; erbB2; erbB3; paclitaxel resistance; Survivin

Indexed keywords

CASPASE 3; CASPASE 8; EPIDERMAL GROWTH FACTOR RECEPTOR 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; SHORT HAIRPIN RNA; SURVIVIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DIMERIZATION; DNA FRAGMENTATION; ENZYME ACTIVATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN TARGETING; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; PACLITAXEL; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; UP-REGULATION;

MAMMALIA;

EID: 77954958218     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.180     Document Type: Article

References (49)

1. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA et al. (1995). Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10: 1813-1821.
2. Altieri DC. (2008). Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8: 61-70.
3. Asanuma H, Torigoe T, Kamiguchi K, Hirohashi Y, Ohmura T, Hirata K et al. (2005). Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res 65: 11018-11025.
4. Bargmann CI, Hung MC, Weinberg RA. (1986). The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319: 226-230.
5. Bieche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R. (2003). Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 106: 758-765.
6. Citri A, Skaria KB, Yarden Y. (2003). The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 284: 54-65.
7. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L et al. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648.
8. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK. (2009). MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 8: 1055-1066.
9. deFazio A, Chiew YE, Sini RL, Janes PW, Sutherland RL. (2000). Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int J Cancer 87: 487-498.
10. Ferlini C, Raspaglio G, Cicchillitti L, Mozzetti S, Prislei S, Bartollino S et al. (2007). Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work? Curr Cancer Drug Targets 7: 704-712.
11. Grupka NL, Lear-Kaul KC, Kleinschmidt-DeMasters BK, Singh M. (2004). Epidermal growth factor receptor status in breast cancer metastases to the central nervous system. Comparison with HER-2/neu status. Arch Pathol Lab Med 128: 974-979.
12. Hawthorne VS, Huang WC, Neal CL, Tseng LM, Hung MC, Yu D. (2009). ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells. Mol Cancer Res 7: 592-600.
13. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas III CF, Hynes NE. (2003). The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 100: 8933-8938.
14. Huang X, Gao L, Wang S, Lee CK, Ordentlich P, Liu B. (2009). HDAC inhibitor SNDX-275 induces apoptosis in erbB2-over-expressing breast cancer cells via down-regulation of erbB3 expression. Cancer Res 69: 8403-8411.
15. Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X et al. (2010). Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res 70: 1204-1214.
16. Hudis CA. (2007). Trastuzumab\mechanism of action and use in clinical practice. N Engl J Med 357: 39-51.
17. Iliopoulos D, Polytarchou C, Hatziapostolou M, Kottakis F, Maroulakou IG, Struhl K et al. (2009). MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal 2: ra62.
18. Jensen EV, Jordan VC. (2003). The estrogen receptor: a model for molecular medicine. Clin Cancer Res 9: 1980-1989.
19. Kim A, Liu B, Ordonez-Ercan D, Alvarez KM, Jones LD, McKimmey C et al. (2005). Functional interaction between mouse erbB3 and wild type rat c-neu in transgenic mouse mammary tumor cells. Breast Cancer Res 7: R708-R718.
20. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L et al. (2003). HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22: 3205-3212.
21. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP et al. (2008). A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 68: 5878-5887.
22. Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD. (2007). Downregulation of erbB3 abrogates erbB2-mediated tam-oxifen resistance in breast cancer cells. Int J Cancer 120: 1874-1882.
23. Liu B, Ordonez-Ercan D, Fan Z, Huang X, Edgerton SM, Yang X et al. (2009). Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling. Mol Cancer Res 7: 1882-1892.
24. Liu Q, Fu H, Xing R, Tie Y, Zhu J, Sun Z et al. (2008). Survivin knockdown combined with apoptin overexpression inhibits cell growth significantly. Cancer Biol Ther 7: 1053-1060.
25. Lu J, Tan M, Huang WC, Li P, Guo H, Tseng LM et al. (2009). Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin Cancer Res 15: 1326-1334.
26. Mita AC, Mita MM, Nawrocki ST, Giles FJ. (2008). Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14: 5000-5005.
27. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. (2006). Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66: 10100-10111.
28. Morris PG, Fornier MN. (2009). Novel anti-tubulin cytotoxic agents for breast cancer. Expert Rev Anticancer Ther 9: 175-185.
29. Nahta R, Esteva FJ. (2007). Trastuzumab: triumphs and tribulations. Oncogene 26: 3637-3643.
30. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. (2006). Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3: 269-280.
31. Oh SH, Jin Q, Kim ES, Khuri FR, Lee HY. (2008). Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mam-malian target of rapamycin-mediated increases in survivin expression. Clin Cancer Res 14: 1581-1589.
32. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. (2003). Mechanisms of Taxol resistance related to microtubules. Oncogene 22: 7280-7295.
33. Pack SD, Alper OM, Stromberg K, Augustus M, Ozdemirli M, Miermont AM et al. (2004). Simultaneous suppression of epidermal growth factor receptor and c-erbB-2 reverses aneuploidy and malignant phenotype of a human ovarian carcinoma cell line. Cancer Res 64: 789-794.
34. Saloustros E, Mavroudis D, Georgoulias V. (2008). Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin Pharmac-other 9: 2603-2616.
35. Schulze WX, Deng L, Mann M. (2005). Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 1: 2005.0008.
36. Seve P, Dumontet C. (2008). Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 9: 168-175.
37. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
38. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
39. Tan M, Jing T, Lan KH, Neal CL, Li P, Lee S et al. (2002). Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol Cell 9: 993-1004.
40. Thor AD, Schwartz LH, Koerner FC, Edgerton SM, Skates SJ, Yin S et al. (1989). Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res 49: 7147-7152.
41. Vaira V, Lee CW, Goel HL, Bosari S, Languino LR, Altieri DC. (2007). Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene 26: 2678-2684.
42. van Amerongen R, Berns A. (2006). TXR1-mediated thrombospondin repression: a novel mechanism of resistance to taxanes? Genes Dev 20: 1975-1981.
43. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726.
44. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A. (1995). Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 14: 4267-4275.
45. Xia W, Bisi J, Strum J, Liu L, Carrick K, Graham KM et al. (2006). Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res 66: 1640-1647.
46. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N et al. (1986). Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319: 230-234.
47. Yu D, Hung MC. (2000). Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19: 6115-6121.
48. Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ et al. (1998). Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Molecular Cell 2: 581-591.
49. Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC. (1996). Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 13: 1359-1365.